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An overview of surveillance methods and systems for Shiga toxin-producing Escherichia coli (STEC) infections is 
available at http://www.cdc.gov/ncezid/dfwed/PDFs/national-stec-surveillance-overiew-508c.pdf (1).
Human Surveillance Data: Laboratory-based Enteric Disease Surveillance (LEDS)
The Laboratory-based Enteric Disease Surveillance (LEDS) system collects reports of isolates from laboratory-confirmed 
human STEC infections from state public health laboratories.  Reporting to LEDS is voluntary, and the number of states 
submitting reports varies somewhat from year to year, although almost all states report every year. Occasionally, more 
than one isolate is reported from a single episode of infection in a person; this report includes only one isolate of a 
given STEC serotype per person within a 30-day period. 
In this report, we summarize the number of infections reported, and also report incidence rates (cases per 100,000 
population), which are calculated as the number of STEC infections in humans reported for a given year divided by 
the reporting state population for that year. For figures and maps, STEC infections reported as “undetermined” are 
categorized as non-O157 STEC infections. 
Data in this report current as of 1/22/2013.
Colorized scanning electron micrograph (SEM) of Gram-negative Escherichia coli O157:H7.
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Table 1. Laboratory-confirmed STEC infections reported to CDC, with the 20 most frequently reported serogroups 
listed individually, United States, 2011
Rank Serogroup Number Reported Percent
1 O157 2366 41.1
2 O26 611 10.6
3 O103 548 9.5
4 O111 322 5.6
5 O121 176 3.1
6 O45 135 2.3
7 O145 74 1.3
8 O118 47 0.8
9 O69 22 0.4
10 O76 14 0.2
11 O91 14 0.2
12 O5 9 0.2
13 O153 8 0.1
14 O104 7 0.1
15 O113 6 0.1
16 O165 6 0.1
17 O174 6 0.1
18 O71 6 0.1
19 O146 5 0.1
20 O80 5 0.1
Sub Total 4387 76.1
All other non-O157 STEC 89 1.5
Unknown* 1200 20.8
Rough 79 1.4
Undetermined 8 0.1
Sub Total 1376 23.9
5763 100
*Infections of an unknown serogroup may represent Shiga toxin-positive stool specimens from 
which no STEC was isolated that were reported as STEC; although they would not meet the 
current case definition for laboratory-confirmed infection, we do not have a way to identify them.
5,763 laboratory-confirmed human STEC infections were reported to CDC through LEDS
 • The top 7 serogroups in 2011 were O157 (41.1%), O26 (10.6%), O103 (9.5%), O111 (5.6%), O121 (3.1%), 
O45 (2.3%), and O145 (1.3%)
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Figure 1. Incidence rate of laboratory-confirmed human STEC infection reported to CDC per 100,000 population,  
                   by serogroup and year, United States, 1996–2011 (n=50,158)
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The overall incidence rate of STEC infection, 1.8 per 100,000 population, was the highest since surveillance began in 
1996  
 • The incidence rate of STEC O157 infection increased in 2011 to 0.76 
 • The incidence rate of infection with non-O157 STEC and STEC serogroups reported as “unknown serogroup” 
increased markedly from 2000 to 2011, likely caused by increased testing of diarrheal stools for Shiga toxin in clinical 
laboratories It is possible that some of the “unknown serogroup” STEC may represent Shiga toxin-positive stool 
specimens from which no STEC was isolated that were reported as STEC; although they would not meet the current 
case definition for laboratory-confirmed infection, we do not have a way to identify them
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Figure 2a. Incidence rate of laboratory-confirmed STEC infection reported to CDC, by state,  
                      United States, 2011 (n=5,763)*
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* Unshaded states are those that reported no STEC infections (no infections were diagnosed or the state did not report to CDC).  
Almost all states reported infections. The overall incidence rate (cases per 100,000 population) was 1.8, the highest 
since surveillance began in 1996 
 • Incidence rates were generally highest in the northern latitude states. The states with the highest reported 
incidence rates were Wisconsin (9.9), Utah (8.3), and Idaho (6.6).
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Figure 2b. Incidence rate of laboratory-confirmed STEC O157 infection reported to CDC, by state,  
                      United States, 2011 (n=2,366)*
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* Unshaded states are those that reported no STEC O157 infections (no infections were diagnosed or the state did not report to CDC).  
48 states reported a total of 2,366 laboratory-confirmed STEC O157 infections, corresponding to an incidence rate 
(cases per 100,000 population) of 0.76  
 • States in the upper Midwest generally had the highest incidence rate, whereas states in the south generally had the 
lowest incidence rates. The states with the highest reported incidence rates were Wisconsin (4.8), South Dakota (4.1), 
and Iowa (2.9) 
Page 6 of 10
Figure 2c. Incidence rate of laboratory-confirmed non-O157 STEC infection reported to CDC, by state,  
                     United States, 2011 (n=2,118)*
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* Unshaded states are those that reported no STEC non-O157 infections (no infections were diagnosed or the state did not report to CDC).   
39 states reported a total of 2,118 laboratory-confirmed non-O157 STEC infections, corresponding to an 
overall incidence rate (cases per 100,000 population) of 0.68 
 • The states with the highest reported incidence rates of non-O157 STEC infection were Idaho (4.3), Utah 
(2.9), and Missouri (2.5) 
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Figure 2d. Incidence rate of laboratory-confirmed  non-O157  STEC infection, top 6 non-O157 STEC serogroups,  
                      reported to CDC  by state, United States, 2011 (n=1,866) 
Legend     Rate per 100,000 population
0.005–0.44 0.45–0.61 0.62–1.04 1.05–1.85 1.86–2.40 No infections were diagnosed or the state did not report to CDC. 
STEC O26 (n=611)
 • 37 states reported 611 laboratory-confirmed STEC O26 
infections, corresponding to an incidence rate (cases 
per 100,000 population) of 0.20 
STEC O103 (n=548)
 • 36 states reported 548 laboratory-confirmed STEC O103 
infections, corresponding to an incidence rate of 0.18 
STEC O111 (n=322)
 • 36 states reported 322 laboratory-confirmed STEC O111 
infections, corresponding to an incidence rate of 0.10
STEC O121 (n=176)
 • 31 states reported 176 laboratory-confirmed STEC O121 
infections, corresponding to an incidence rate of 0.06
STEC O45 (n=135)
 • 21 states reported 135 laboratory-confirmed STEC O45 
infections, corresponding to an incidence rate of 0.04
STEC O145 (n=74)
 • 25 states reported 74 laboratory-confirmed STEC O145 
infections, corresponding to an incidence rate of 0.02
The 6 non-O157 STEC serogroups that caused the most infections during 2010 were O26, O103, O111, O145, O121 and O45. 
Fewer states reported laboratory-confirmed non-O157 STEC infections to LEDS than reported laboratory-confirmed STEC O157 
infections. This reflects substantial state-to-state variation in clinical testing practices and public health reporting practices. See 
the National STEC Surveillance Overview http://www.cdc.gov/ncezid/dfwed/PDFs/national-stec-surveillance-overiew-508c.pdf  
for further information. 
 • Idaho had the highest reported incidence rate of laboratory-confirmed STEC O26 and O121 infections, while Wisconsin had 
the highest incidence rate of laboratory-confirmed STEC O103 and STEC O45 infections, and Iowa had the highest incidence 
rate of laboratory-confirmed STEC O111 and STEC O145 infections. 
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Figure 3a. Incidence rate of laboratory-confirmed STEC O157 infection reported to CDC, by age group and sex, 
                      United States, 2011 (n=2,235)
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During 2011, the highest incidence rates of STEC O157 infection were in children under 5 years old; this rate was nearly 
double the incidence rate in children 5 to 9 years old for both males and females  
 • The incidence rate of STEC O157 infection was slightly higher in males aged 0 to 19 years than females in the same 
age group but higher in females than males 20 years and older
Figure 3b. Incidence rate of laboratory-confirmed non-O157 STEC infection reported to CDC, by age group and sex,  
                      United States, 2011 (n=2,014)
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During 2011, the highest incidence rates of infection with non-O157 STEC were in children under 5 years old; this 
rate was nearly 3 to 4 times the incidence rate in children 5 to 9 years old
 • Incidence rates of non-O157 STEC infection in females were higher than males in the same age groups, except in 
males 5 to 19 years old
Page 9 of 10
Figure 4. Number of laboratory-confirmed STEC O157 infections reported to CDC by month of specimen collection,  
                   United States, 2011 and average annual number during 2001–2010
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During 2011, laboratory-confirmed STEC O157 infections peaked in the summer and fall 
Figure 5. Number of laboratory-confirmed non-O157 STEC infections reported to CDC by month of specimen  
                   collection, United States, 2011 and average annual number during 2001–2010
Month of Specimen Collection
0
50
100
150
200
250
350
300
400
0
10
20
30
40
50
60
80
70
90
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
N
um
be
r o
f  
la
bo
ra
to
ry
-c
on
fir
m
ed
 n
on
-O
15
7
ST
EC
 in
fe
ct
io
ns
 re
po
rt
ed
 to
 C
D
C
 in
 2
01
1
N
um
be
r o
f l
ab
or
at
or
y-
co
nf
irm
ed
  n
on
-O
15
7 
ST
EC
in
fe
ct
io
ns
 re
po
rt
ed
 to
 C
D
C
 d
ur
in
g 
20
01
–2
01
02011 2001–2010
During 2011, non-O157 STEC infections peaked in the summer and the seasonality was similar to the average annual 
number during 2001–2010
 • For the first year, there were more laboratory-confirmed non-O157 STEC infections than STEC O157 infections from 
December through May 
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Human Reference Laboratory Data: National Escherichia coli Reference  
Laboratory Data
The National Escherichia coli Reference Laboratory receives unusual or untypable isolates  from state public health 
laboratories for further characterization, including identification and serotyping of non-O157 STEC and identification of 
Shiga toxins and other virulence factors. It also receives clinical specimens for isolation of STEC. The number of isolates 
submitted to the National Escherichia coli Reference Laboratory are reported with specimen submission rates. The 
non-O157 STEC specimen submission rate is the number of presumptive non-O157 STEC isolates and Shiga toxin-positive 
enrichment culture broths submitted to CDC for further characterization for a given year, divided by the population 
for that year. Submission to the National Escherichia coli Reference Laboratory is voluntary, and the number of states 
submitting isolates varies from year to year. 
 • Data from the National Escherichia coli Reference Laboratory will be included here when available.
Human Surveillance Data: National Notifiable Diseases Surveillance Systems (NNDSS)
The National Notifiable Disease Surveillance System (NNDSS) collects and compiles reports of nationally notifiable 
infectious diseases, including STEC. This system includes reports of culture-confirmed, probable and suspected cases.  
The case definition is available at  http://wwwn.cdc.gov/nndss/document/2012_Case%20Definitions.pdf. 
The 2011 NNDSS report is not yet available, but when available will be posted at: 
http://www.cdc.gov/mmwr/mmwr_nd/index.html
Human Antimicrobial Resistance Data: National Antimicrobial Resistance Monitoring 
System (NARMS)
The National Antimicrobial Resistance Monitoring System (NARMS) monitors antimicrobial resistance among enteric 
bacteria isolated from humans. NARMS uses the classes of antimicrobial agents defined by the Clinical and Laboratory 
Standards Institute (CLSI). The 2011 NARMS report on human isolates is not yet available, but when available, it will be 
posted at http://www.cdc.gov/narms/reports.html (2). 
Human Outbreak Data: Foodborne Disease Outbreak Surveillance System (FDOSS) 
and Waterborne Disease Outbreak Surveillance System (WBDOSS)
The Foodborne Disease Outbreak Surveillance System (FDOSS) collects reports of foodborne disease outbreaks from local, 
state, tribal, and territorial public health agencies. Reports can be found at   
http://www.cdc.gov/outbreaknet/surveillance_data.html.
The Waterborne Disease and Outbreak Surveillance System (WBDOSS) collects reports of disease outbreaks associated 
with drinking water and recreational water from local, state, tribal, and territorial public health agencies. Reports can be 
found at http://www.cdc.gov/healthywater/statistics/wbdoss/surveillance.html.
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